- Home
- DGX
as 07-26-2024 4:00pm EST
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
| Founded: | 1967 | Country: | United States |
| Employees: | N/A | City: | SECAUCUS |
| Market Cap: | 15.3B | IPO Year: | 1996 |
| Target Price: | $150.85 | AVG Volume (30 days): | 972.3K |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.41 | EPS Growth: | 7.08 |
| 52 Week Low/High: | $119.59 - $150.59 | Next Earning Date: | 07-23-2024 |
| Revenue: | $9,346,000,000 | Revenue Growth: | -1.50% |
| Revenue Growth (this year): | 3.13% | Revenue Growth (next year): | 3.37% |
Stock Insider Trading Activity of Quest Diagnostics Incorporated (DGX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KUPPUSAMY KARTHIK | DGX | SVP, Clinical Solutions | Apr 29 '24 | Sell | $140.00 | 1,760 | $246,400.00 | 13,435 | SEC Form 4 |
| Doherty Catherine T. | DGX | EVP, Regional Businesses | Feb 28 '24 | Sell | $125.88 | 1,187 | $149,419.56 | 68,412 | SEC Form 4 |
| Doherty Catherine T. | DGX | EVP, Regional Businesses | Feb 28 '24 | Sell | $126.57 | 5,557 | $703,349.49 | 69,599 | SEC Form 4 |
| PREVOZNIK MICHAEL E | DGX | SVP & General Counsel | Feb 28 '24 | Sell | $125.88 | 5,611 | $706,312.68 | 38,478 | SEC Form 4 |
| Gregg Vicky B | DGX | Director | Feb 23 '24 | Sell | $126.64 | 2,500 | $316,596.50 | 16,329 | SEC Form 4 |
| Doherty Catherine T. | DGX | EVP, Regional Businesses | Feb 21 '24 | Sell | $126.14 | 821 | $103,560.94 | 70,800 | SEC Form 4 |
| PREVOZNIK MICHAEL E | DGX | SVP & General Counsel | Feb 21 '24 | Sell | $126.14 | 661 | $83,378.54 | 40,206 | SEC Form 4 |
Latest Quest Diagnostics Incorporated News
DGX Breaking Stock News: Dive into DGX Ticker-Specific Updates for Smart Investing
MT Newswires
6 hours ago
Mizuho Securities Raises Quest Diagnostics' Price Target to $160 From $155
Zacks
8 hours ago
Integer Holdings (ITGR) Q2 Earnings Top Estimates, Margins Up
Zacks
8 hours ago
DexCom's (DXCM) Q2 Earnings Beat Estimates, Revenues Miss
Zacks
9 hours ago
Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions
Zacks
13 hours ago
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down
GuruFocus.com
20 hours ago
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight
MT Newswires
a day ago
Becton, Dickinson Partners With Quest Diagnostics on Flow Cytometry-Based Companion Diagnostics
Zacks
a day ago
Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms
Compare DGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DGX Quest Diagnostics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.